Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ferric oxyhydroxide is an inorganic compound with the formula FeO(OH), also known as iron(III) oxide-hydroxide. It is used as a phosphate binder to treat hyperphosphatemia in patients with chronic kidney disease (CKD), particularly those on dialysis[1][3][4]. The drug acts by binding dietary phosphate in the gastrointestinal tract through ligand exchange between its hydroxyl groups and dietary phosphate, forming an insoluble complex that is excreted in feces[5]. This reduces serum phosphorus levels and the calcium-phosphorus product. Ferric oxyhydroxide itself is practically insoluble and not systemically absorbed. It constitutes the core of natural ferritin and exists as a colloid in pharmaceutical preparations[1][2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ferric oxyhydroxide.